Skip to main content
Quest Diagnostics

Cross-reactivity of Designer Benzodiazepines in Point-of-care Urine Drug Screening Cups

ADLM 2026

Association for Diagnostics and Laboratory Medicine

Anaheim, CA, June 26-30, 2026

Poster presentation: Cross-reactivity of Designer Benzodiazepines in Point-of-care Urine Drug Screening Cups

Authors: Jillian Neifeld, Theresa M Meli, Alicia A Bland, and Sarah H Bartock

Medical Specialty: Prescription Drug Monitoring, Toxicology

Related content

Audio Podcast
Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue
On-Demand Webinar
The Growing Crisis of Novel Psychoactive Substances
Audio Podcast
Drug Testing for Stimulants
Test FAQ
Drug Toxicology Monitoring Oral Fluid Testing
Test FAQ
Drug Monitoring Antidepressants With Confirmation Urine and Serum
Test FAQ
Pain Management Antipsychotics With Confirmation Serum and Urine

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.